A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG 10% IN PATIENTS WITH DERMATOMYOSITIS. THE PRODERM STUDY: RESULTS ON EFFICACY AND SAFETY

被引：4

作者：

Aggarwal, R. ^{[1
]}

Charles-Schoeman, C. ^{[2
]}

Schessl, J. ^{[3
]}

Bata-Csorgo, Z. ^{[4
]}

Dimachkie, M. ^{[5
]}

Griger, Z. ^{[6
]}

Moiseev, S. ^{[7
]}

Oddis, C. V. ^{[8
]}

Schiopu, E. ^{[9
]}

Vencovsky, J. ^{[10
]}

Beckmann, I. ^{[11
]}

Levine, T. ^{[12
]}

Clodi, E. ^{[13
]}

机构：

[1] Univ Pittsburgh, Rheumatol, Pittsburgh, PA USA

[2] UCLA Hlth, Rheumatol, Los Angeles, CA USA

[3] Univ Munich, Friedrich Baur Inst, Neurol, Munich, Germany

[4] Univ Szeged, Fac Med, Dermatol, Szeged, Hungary

[5] Univ Kansas, Med Ctr, Neurol, Kansas City, KS USA

[6] Univ Debrecen, Dept Internal Med, Debrecen, Hungary

[7] First Moscow State Med Univ, Dept Internal Med, Moscow, Russia

[8] Univ Pittsburgh, Rheumatol, Pittsburgh, PA USA

[9] Michigan Med, Rheumatol, Ann Arbor, MI USA

[10] Charles Univ Prague, Rheumatol, Prague, Czech Republic

[11] Clin R&D, Octapharma PPG, Vienna, Austria

[12] Phoenix Neurol Associates, Neurol, Phoenix, AZ USA

[13] Global Med Sci Affairs, Octapharma PPG, Vienna, Austria

[14] Hosp different countries worldwide, Rheumatol Dermatol Neurol, Vienna, Austria

来源：

关键词：

D O I：

10.1136/annrheumdis-2021-eular.1389

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0008

引用

页码：4 / 5

页数：2

共 1 条